Submission date
04/12/2006
Registration date
26/01/2007
Last edited
01/11/2022
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Mental and Behavioural Disorders
Retrospectively registered
? Protocol not yet added
? SAP not yet added
Results added
? Raw data not yet added
Study completed

Plain English Summary

Not provided at time of registration

Study website

Contact information

Type

Scientific

Contact name

Dr Stefan Klingberg

ORCID ID

Contact details

Osianderstr. 24
Tuebingen
72076
Germany

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Protocol/serial number

N/A

Study information

Scientific title

-

Acronym

POSITIVE

Study hypothesis

Cognitive Behavioural Treatment (CBT ) is more efficacious in reducing positive symptoms than Supportive Therapy (ST).

Ethics approval(s)

Ethics Commitee of the Medical Faculty, University of Tuebingen; date of approval: 27 October 2006

Study design

Randomised, single blind, parallel group, prospective, controlled study comparing a specific treatment with an unspecific, “placebo”-attention control group

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Other

Study type

Treatment

Patient information sheet

Condition

Psychotic disorders (schizophrenia, schizophreniform, schizoaffective and delusional disorders)

Intervention

Cognitive Behavioural Treatment versus Supportive Therapy

Intervention type

Other

Primary outcome measure

Primary endpoint for efficacy: PANSS positive syndrome (sum of items P1-P7), assessed post treatment (T9).

Secondary outcome measures

Key secondary endpoints:
1. Additional symptom ratings (e.g. PSYRATS)
2. Social functioning
3. Illness related events
4. Quality of life
5. Questionnaires about self schemata and interpersonal schemata
6. Direct and indirect costs

Assessment of safety:
1. Death
2. Suicidal behaviour
3. Severe depressive symptom exacerbation

Overall study start date

01/01/2007

Overall study end date

31/12/2008

Reason abandoned (if study stopped)

Eligibility

Participant inclusion criteria

1. Schizophrenia, schizophreniform, schizoaffective, delusional disorders (according to Diagnostic and Statistical Manual of Mental Disorders - fourth edition [DSM-IV])
2. Score of four or more on the Positive and Negative Syndrome Scale (PANSS)-items “delusions” or “hallucinations”
3. Presence of these symptoms for at least three months

Participant type(s)

Patient

Age group

Not Specified

Sex

Not Specified

Target number of participants

260

Total final enrolment

233

Participant exclusion criteria

1. Substance abuse or substance dependence as primary clinical problem
2. Organic brain disease

Recruitment start date

01/01/2007

Recruitment end date

31/12/2008

Locations

Countries of recruitment

Germany

Study participating centre

Osianderstr. 24
Tuebingen
72076
Germany

Sponsor information

Organisation

University Hospital Tuebingen (Germany)

Sponsor details

Geissweg 3
Tuebingen
72076
Germany

Sponsor type

University/education

Website

http://www.medizin.uni-tuebingen.de

ROR

https://ror.org/00pjgxh97

Funders

Funder type

Research organisation

Funder name

German Ministry of Education and Research (Bundesministerium für Bildung und Forschung, BMBF; 01GV0618)

Alternative name(s)

Funding Body Type

Funding Body Subtype

Location

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

Not provided at time of registration

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?
Results article secondary analysis 10/02/2020 12/02/2020 Yes No
Results article secondary analysis 23/11/2020 25/11/2020 Yes No

Additional files

Editorial Notes

01/11/2022: Total final enrolment added. 25/11/2020: Publication reference added. 12/02/2020: Publication reference added.